Neutra Corporation (ID) (NTRR)

Here’s my breakdown:
1. New Joint Venture = Another Revenue-Producing Site
The biggest announcement was that Neutra Life Sciences formed a joint venture with a Women’s Healthcare Center in Baytown, Texas.
This is important because:
It expands the company’s clinical research network.It adds OB/GYN and Women’s Health as a new specialty.More specialties make the company more attractive to pharmaceutical sponsors looking for trial sites.Instead of relying on one or two clinics, they’re building a diversified site network.  

2. Four New Therapeutic Areas
The release says Neutra Life Sciences was awarded studies in:
OncologyPulmonologyDermatologyWomen’s HealthThat’s significant because oncology studies especially can be among the higher-value clinical trials.
The more therapeutic areas they support, the larger their potential pipeline of future studies.  

3. New Sponsor Contracts
This may be the most overlooked part.
The company announced:
New sponsorsAdditional contracts with existing sponsorsSponsors are typically pharmaceutical or biotech companies paying for clinical trials.
Repeat business suggests previous trial execution has been satisfactory enough for sponsors to continue working with them. That’s generally a positive operational signal.  

4. They Emphasized Operational Infrastructure
The release states they’ve developed:
Standard operating proceduresExpanded investigator networkRegulatory-compliant trial executionScalable operating modelThat language suggests management believes they’ve moved beyond the startup phase and are building systems capable of handling more trial volume.  

5. Looking Ahead
Management said they expect:
More clinical trialsMore sponsor relationshipsContinued growth in the second half of 2026

Agreed 

Encouraging update. Just need to see what kind of publicity or interest. It seems the direction is positive but not reflecting in the stock price. We need investor interest to move the price. A gradual increase prior to the third quarter financial results would be great.

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial. Since its formation, Neutra Life Sciences has built the operational infrastructure required to support a sustainable, scalable site network, including standardized site operating procedures, an expanding investigator base, and a consistent track record of regulatory-compliant trial execution. This foundation has allowed the subsidiary to move from an early-growth phase into a stable operating model capable of supporting a broader, more diverse clinical trial portfolio.As part of this expansion, Neutra Life Sciences executed a new joint venture partnership with Women’s Healthcare Center of Baytown, which expanded its site network dedicated into women’s health. The new site broadens Neutra Life Sciences’ specialty footprint beyond its existing network and reflects increasing demand from sponsors for clinical trial access in women’s health research.“Growing into a multi-therapeutic site network was done with intention,” said Sydney Jim, President and CEO of Neutra Life Sciences. “This new joint venture and the launch of our women’s health site solidify our growth strategy, and we are proud to extend OB/GYN clinical trial access to patients.”Alongside this expansion, Neutra Life Sciences was awarded new clinical trials in Oncology, Dermatology, Pulmonology, and Women’s Health, broadening the range of conditions studied across its site network. The subsidiary also secured new contracts with new sponsors, further diversifying its sponsor relationships and strengthening its trial pipeline heading into the second half of 2026.“Being awarded studies in new therapeutic areas and signing new sponsor contracts is a direct result of the operational discipline we’ve built over the past year,” added Sydney Jim. “Each new study and each new sponsor relationship adds depth to our pipeline and reinforces Neutra Life Sciences as a dependable SMO partner.”Recent milestones at Neutra Life Sciences include:Looking ahead to the third and fourth quarters of 2026, Neutra Corp expects continued growth across its existing and new therapeutic areas. The Company anticipates additional new trial opportunities, and continued expansion of its sponsor and CRO relationships. Management believes that showcasing our abilities in each and every trial awarded will position the subsidiary to scale its trial volume and sponsor relationships through the remainder of 2026

I get that but Q1 results don’t lie. Continued improvement. 

I'm not holding my breath. Syd has failed in the past to keep commitments. It's better to say nothing than promise and not deliver. We are still waiting from updates from the last filing.

1. Revenue Growth
This is the most important metric.
Questions to ask:

If revenue grows meaningfully quarter-over-quarter, it would support management’s growth narrative.
2. Cash Flow and Operating Results
Revenue alone isn’t enough.
Look for:

A company moving toward cash-flow breakeven often attracts more investor interest than one simply growing revenue.
3. Site and Study Expansion
This is the future-growth indicator.
Look for:

Even if Q2 profits are modest, announcements showing expansion of the site network could signal stronger revenue in future quarters.1. Revenue Growth
This is the most important metric.
Questions to ask:

If revenue grows meaningfully quarter-over-quarter, it would support management’s growth narrative.
2. Cash Flow and Operating Results
Revenue alone isn’t enough.
Look for:

A company moving toward cash-flow breakeven often attracts more investor interest than one simply growing revenue.
3. Site and Study Expansion
This is the future-growth indicator.
Look for:

Even if Q2 profits are modest, announcements showing expansion of the site network could signal stronger revenue in future quarters.

Quick overview: The Big Positive: Revenue Growth
Revenue jumped to $352,811 versus $68,057 in the same quarter last year — an increase of more than 400%. Most of the revenue came from the Neutra Life Sciences clinical research business, which generated approximately $325,811 during the quarter.  
Profitability
The company reported a net profit of $84,505, compared to a loss of $109,023 in the prior-year quarter. This is a significant improvement and one of the strongest numbers shareholders have seen from NTRR.  
No Dilution During the Quarter
Common shares outstanding remained at 2.917 billion shares, the same as the previous quarter. No new common stock was issued during Q1.  
Share Cancellation
The company disclosed that 125 million shares were cancelled in February 2026 after a service agreement with Pacific Capital Markets was terminated.  
Cash Position
Cash increased from about $36,743 at January 31, 2026 to $49,910 at April 30, 2026. Operating activities generated positive cash flow of approximately $65,284.  
Balance Sheet Concerns
The company still has:

Management specifically states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.  
Neutra Life Sciences Continues to Drive the Story
The filing confirms that the clinical research subsidiary, Neutra Life Sciences (NLS), is now the primary growth engine. NLS operates clinical research sites across multiple specialties and generated the vast majority of Q1 revenue.  
My Overall Assessment
For NTRR shareholders, this was probably the strongest quarterly filing in years because:

The biggest negatives remain:

For the next quarter, I’d focus on three things:

Q1 https://www.otcmarkets.com/file/company/financial-report/572606/content

I knew it. Damn you. 

Sorry Jay, I may have let the group down. It was my responsibility to remind Syd the filing was due. I will do better next time.

Looks like we will be waiting till Monday for their filing unless they file an extension. 

Let’s try this again: 

📊 What the “end of year baseline” tells us
From recent reported history, NTRR has generally shown:
📉 1. Very small revenue base
Latest annual revenue: ~$39K–$68K range (depending on year)

TTM most recently reported: ~$66K–$823K range depending on accounting window/source variation

Most consistent confirmed core level:

👉 ~$40K–$70K annualized baseline
📌 Meaning:

This is a micro-revenue operation, not a scaled business yet.


📉 2. Revenue is volatile, not steadily growing
One year up, next year down

Example pattern:

~$92K ? $68K ? $39K (decline trend overall)
📌 Meaning:

Growth is inconsistent and not compounding yet


📉 3. Persistent net losses
Annual net income: roughly -$200K to -$600K+

Operating margin: deeply negative (often -400% to -800%)
📌 Meaning:

Revenue is not yet covering fixed costs


📉 4. Shares outstanding continue to expand
Billions of shares outstanding (~3B+ range)

Year-over-year increases common
📌 Meaning:

Funding operations often relies on equity dilution


🧭 What this means going into Q1
This baseline sets expectations:
🟡 Revenue expectation anchor:
Most realistic Q1 range:

👉 $20K ? $150K
Because:

That’s consistent with historical quarterly pacing

Requires no major structural change


🟢 “Good Q1” relative to baseline:
Anything above:

👉 $150K–$400K
Would mean:

Clear improvement vs historical run-rate

First sign of scaling beyond legacy baseline


🚀 “Breakout Q1” (rare for this structure):
$400K–$1M+
Would imply:

Business model shift or real expansion

Not just continuation of past performance


⚠️ Key takeaway investors often miss
For NTRR:
The baseline revenue (~$40K–$70K annually) is so small that even “doubling revenue” does NOT automatically change valuation.
Instead, the market reacts more to:

dilution slowing

new contracts

liquidity spikes

narrative changes


💡 Simple interpretation
The end-of-year baseline tells us:
🟡 This is a low-revenue, high-dilution microcap

🟡 Q1 is unlikely to deviate massively without a catalyst

🟢 Even “good results” are still small in absolute dollars

🚨 Price movement is structurally disconnected from earnings

Ugh this site sucks. Again didn’t pull all my information over. Will try again in an updated post 

Thoughts and scenarios as we wait on Q1 based off of year end results. 
📊 What the “end of year baseline” tells us
From recent reported history, NTRR has generally shown:

So the baseline going into Q1 is essentially:
“small revenue base, early-stage operations, unproven scaling”


🔮 What we can realistically expect in Q1
🟡 Most likely outcome (base case)
This is what most OTC investors should assume unless proven otherwise:

👉 This would be considered “progress narrative, but not financial breakout”


🟢 Positive surprise scenario (bullish Q1)
This is what would actually get attention:

👉 This could support a move toward $0.001+ range if sustained


🔴 Weak scenario (bearish Q1)
If nothing has meaningfully changed:

👉 Market reaction: likely sell-off or no sustained momentum


⚠️ The most important thing investors miss
For NTRR, the market will NOT react strongly to:

It WILL react to:



🧭 Big picture expectation
Realistically, Q1 is likely to be:



💡 Simple takeaway

Very frustrating for sure.  

So it appears Syd has failed us again. Syd promised updates following the last financial report and followed up with nothing. He will never be a a leader with integrity. Once again, we are coming up on a 10Q with no updates. Syd is awful....

Insider has majority share at .0002
Amy be it will bounce very hard back

Sydney get a new Mercedes?

hmmm...what makes you think that?

Looks like something is going on behind the scene.

Nice job Jay....

Summary of changes: 

Amended filing https://www.otcmarkets.com/file/company/financial-report/549076/content

Last attempt
I’m adding as a photo so hopefully everything comes through. 

I give up with this site. Didn’t keep half of what I entered 

Sry not sure what happened to my last post. Let’s try this again 
My takeaway: 
Revenue & Profitability

Net Loss

Observation: Revenue growth is strong for a small nutraceutical company. The near break-even net loss is encouraging, showing improved operational efficiency and expense management.
Balance Sheet HighlightsObservation: The company has improved its liquidity and reduced liabilities substantially. Assets are still modest, reflecting early-stage operations.
Debt and Related Party TransactionsKey Risks & Considerations
Summary Analysis

My takeaways: 
Revenue & Profitability







Net Loss





Observation: Revenue growth is strong for a small nutraceutical company. The near break-even net loss is encouraging, showing improved operational efficiency and expense management.





Observation: The company has improved its liquidity and reduced liabilities substantially. Assets are still modest, reflecting early-stage operations.




Key Risks & Considerations

10K filing out https://www.otcmarkets.com/file/company/financial-report/546109/content

Some volume today.....

A new development worth noting for fellow investors following Neutra Life Sciences: one of the physicians associated with their research network, Dr. Liet N. Le of Radiant Dermatology & Aesthetics, has opened an additional clinic location in Dayton, Texas (108A N Main St). While a newly opened clinic does not automatically become an approved clinical trial site, expansions like this can be meaningful for a site management organization such as Neutra. When investigators add new offices, those locations can potentially be approved later as satellite enrollment or full research sites once regulatory and sponsor approvals are obtained. Additional locations expand patient access and recruitment capacity, which is a key factor in how quickly trials can enroll participants. For early-stage research networks, the growth of affiliated clinics and investigators can be an indicator of expanding infrastructure that may support more clinical trials over time.

It seems Syd has finally added the 9th location to the Neutra Life Sciences website. It was announced in October but not added until recently. Seems to have an uptick in buying yesterday as well.

I’m pretty confident now even without an official announcement that from the 125 million shares returned and now also seeing that Neutra Corp has removed Zac Logan of Pacific Capital Markets from their OTC page that they did in fact cut ties with them thank goodness. Hopefully they listen and do some actual DD before they engage with another firm. 

Good time to acquire more shares here when ticker is at bottom

I am a little curious I know there are a lot of issues With NTRR but it seems like it’s trading very little at prices of  0002That’s almost the bottom bottom yet nobody seems to buy

That is great. We just need updates from the company.
Share structure is good here

If Syd did depart with Zack, it would not surprise me. His background and past history is a predictable indicator of success or failure. A poor decision to bring him aboard. Any firm sanctioned by the SEC for misconduct should of been disqualified.

Interesting:Share count was 3,042,899,124 as of December 2025 and now is back down to 2,917,899,124 as of March 2026. That’s 125,000,000 shares returned which at .0002 = $25,000 which lines up with what they paid Pacific Capital Markets 🤔 Guess they finally realized what we were trying to warn them about Zack. Looks like they pulled payment back. If so that’s great. Guess we will find out if they are looking again for another IR Firm. 
3,042,899,124 as of December 15, 2025
Outstanding Shares2,917,899,12403/03/2026

Will there be a 10q in March or will the 4th quarter be in the 10K?

That response was from Neutra Corp 

I reached out regarding the lack of communication especially from Neutra Life Sciences on their Twitter account. Reply I received : 
we are, just late on posts, we'll be getting caught up this month

Wow...no updates or posts in a while. I sent a message to Syd on X but never got a response. I believe on the alternative filing with OTC that a 4th quarter 10Q was required. I posed the question to Syd and he did not respond. Hopefully, we will hear good news soon.

Almost 50MM volume today

One day NTRR will be huge
Great updates foe 2026
Revenue growth 1000%
$NTRR
Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Yearhttps://t.co/oPmY2zu2io— JEET (@TheJeet13) January 26, 2026

Gonna take time my guess given their past financial history. 

It seems there is no market interest in NTRR. SMH

Good find. I don't have an account set up with Newmediawire. Guess I may have to to get alerts from them. 

This seems to be a strong step forward for Ntrr....

2026 UPDATE!!!!

https://finance.yahoo.com/news/neutra-corp-successfully-pivots-business-120000372.html

If I'm not mistaken I believe this is the first post I've seen by NLS for Epic Foot & Ankle Centers conduting study's. That's another step forward if so. Happy New Year 
Do you have a wound that won't heal? pic.twitter.com/opUariqJMQ— Neutra Life Sciences (@NeutraLifeSci) December 31, 2025